Spinogenix Expands CLARITY Trial to Autism with EEG-Based Precision Enrollment
Event summary
- Spinogenix adds Phase 2b autism study to CLARITY basket trial (NCT07439510), marking its first autism-focused trial.
- Novel EEG-based enrollment targets 22% of autism patients (32% of adults) with elevated gamma band power, a biomarker linked to Fragile X syndrome.
- Codabakalner (SPG601) previously reduced gamma power and improved executive function in FXS Phase 2a study.
- Study co-authored by Cincinnati Children's Hospital found no clinical differences between biomarker-positive and -negative autism subgroups.
The big picture
Spinogenix's biomarker-enriched approach addresses a critical challenge in autism drug development: patient heterogeneity. While most trials enroll based on behavioral criteria, this EEG-based strategy could become a model for precision medicine in neurodevelopmental disorders. The company's dual focus on Fragile X and autism positions it uniquely in the synaptic regenerative therapeutics space, though success will depend on demonstrating consistent biomarker-drug response relationships across conditions.
What we're watching
- Biomarker Validation
- Whether elevated gamma power proves a reliable predictor of codabakalner efficacy in autism patients.
- Precision Medicine Adoption
- The pace at which EEG-based enrollment strategies become standard in neurodevelopmental drug trials.
- Regulatory Pathways
- How FDA's Fast Track designation for codabakalner in FXS may influence autism indication approvals.